摘要
研究背景
内皮功能紊乱、脂质代谢异常及炎症反应在冠状动脉粥样硬化发生过程中相互作用,形成极其复杂的病理生理学过程。非对称性二甲基精氨酸(ADMA)是内皮型一氧化氮合酶的内源性竞争性抑制剂,它使内皮一氧化氮合成减少,造成内皮功能紊乱。内皮功能紊乱先于冠状动脉粥样硬化发生,并可能导致冠状动脉粥样硬化发生和进展。近年研究发现ADMA与原发性高血压病、高脂血症、糖尿病及高同型半胱氨酸血症等心血管疾病的危险因素相关,但中国人群的ADMA与冠心病预后关系较全面的研究较少。
研究目的
1、建立高效液相色谱联合串联质谱(HPLC-MS/MS)分析样本ADMA相关指标的方法；
2、测定对照组、稳定心绞痛组及急性冠脉综合征组患者血浆样本的ADMA相关指标水平(包括ADMA、对称性二甲基精氨酸(SDMA)、精氨酸(Arg)、瓜氨酸(Cit)、鸟氨酸(Orn)),并探讨其与冠心病及其预后之间的关系。
研究方法
1、建立HPLC-MS/MS分析样本ADMA相关指标的方法,考察其特异性、敏感度和批内、批间准确度和精密度；并测定入选病例血浆ADMA相关指标水平；
2、收集2007年2月至2009年6月,于北京协和医院心内科病房、CCU及急诊住院,行冠状动脉造影术诊断为冠脉正常、稳定心绞痛及急性冠脉综合征患者的血浆样本及临床资料,并随访其2年预后,探讨ADMA相关指标与冠心病及其预后之间的关系。
结果
1、成功建立HPLC-MS/MS测量ADMA相关指标的方法,并通过方法学考察；
2、入选病例共170例,其中对照组20例,稳定心绞痛组45例,急性冠脉综合征组105例(不稳定心绞痛组40例,非ST段抬高型心肌梗死组25例,ST段抬高型心肌梗死组40例),共获得155例随访结果；
3、经统计发现ADMA相关指标在冠心病各组间存在明显差异；ADMA水平与TC、 LVEF、BNP等临床及生化指标独立相关；ADMA水平与冠脉病变的范围与严重程度相关；比值Arg/ADMA、Arg+Cit+Orn/ADMA+SDMA是冠心病的独立危险因素；比值Arg/ADMA、Arg+Cit+Orn/ADMA+SDMA是冠心病预后的独立预测因子。
结论
1、成功建立HPLC-MS/MS分析样本ADMA相关指标的方法；
2、ADMA相关指标是冠心病的独立危险因素,且与其预后密切相关。
Background
Endothelial dysfunction, dyslipidemia and inflammation play critical roles in the process of coronary atherosclerosis. Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of endothelial nitric oxide synthase and an important cause of endothelial dysfunction. Its elevated plasma concentration is associated with a variety of traditional cardiovascular risk factors, and may mediate their effects on vascular endothelium dysfunction. Many studies have implicated ADMA is an independent predictor of coronary artery disease, but rare studies focus on the association between ADMA level and the prognosis of coronary artery disease in Chinese.
Objectives
1. Establish the high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for the analysis of asymmetric dimethylarginine relevant items (including ADMA, SDMA, Arginine, Citrulline and Ornithine) in human plasma.
2. Determine the ADMA level of plasma sample from patients in the group of control, stable angina pectoris (SAP) and acute coronary syndrome (ACS) by means of HPLC-MS/MS, and investigate the relationship between ADMA and coronary artery disease and its prognosis.
Method
1. Build the HPLC-MS/MS method for the analysis of asymmetric dimethylarginine relevant items, and examine its specificity, sensitivity and intra-and inter-batch accuracy and precision.
2. Consecutive patients referred to the ward of cardiology department, cardiac care unit and emergency of PUMC for percutaneous coronary intervention from February2007to June2009are enrolled in this study, and their plasma samples and clinical information are collected after informed consent. They are followed up prospectively for2years and the major adverse cardiac events are considered as terminal event. The ADMA levels are determined by HPLC-MS/MS.
Results
1. Established the HPLC-MS/MS method for the analysis of asymmetric dimethylarginine relevant items successfully and it passed methodology examination.
2. A total of170cases are selected, including20cases in control group,45patients in SAP group,105cases in the ACS group, and received follow-up results from155patients.
3. The statistics result indicates that significant difference of ADMA relevant items exists among the groups; ADMA concentration correlates with total cholesterol, left ventricle ejection fraction, brain natriuretic peptide and other clinical and biochemical parameters; ADMA concentration is associated with the extent and severity of coronary lesion; ADMA relevant ratios are independent risk factors of coronary disease and independent predict its prognosis.
Conclusion
1. Establish the HPLC-MS/MS method for the analysis of asymmetric dimethylarginine relevant items.
2. ADMA relevant items are independent risk factors of coronary disease, and are closely related to its prognosis.
引文
1. Libby P. Inflammation in atherosclerosis. Nature.2002;420:868-874.
2. Vogel RA. Coronary risk factors, endothelial function, and atherosclerosis:A review. Clin Cardiol 2009;20(5):426-432.
3. Murad F. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med.2006; 355:2003-2011.
4. John P Cooke. Does ADMA Cause Endothelial Dysfunction? Arterioscler Thromb Vasc Biol.2000; 20:2032-2037.
5. Suwaidi JA, Hamasaki S, Higano ST, Nishiraura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation.2000; 101:948-954.
6. James M. Leiper, Patrick Vallance. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol. 2006; 62:33-38.
7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol.1992;20(suppl 12):S60-S62.
8. Ulrich Forstermann and Thomas Munzel. Endothelial Nitric Oxide Synthase in Vascular Disease:From Marvel to Menace. Circulation.2006; 113; 1708-1714.
9. L Vladimirova-Kitova, T Deneva, E Angelova, F Nikolov, B Marinov and N Mateva. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging,2008; 28:417-425.
10. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol.1999;33:652-8.
11. Krzyzanowska K, Mittermayer F, Shnawa N, et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med 2007;24:81-6.
12. Markus CS, Roberta KO, Eric EG, Isabella S, et al. Endothelial Dysfunction Induced by Hyperhomocyst(e)inemia:Role of Asymmetric Dimethylarginine. Circulation. 2003;108:933-938.
13. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease:results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152:493.e1-8.
14. Lu TM, Yu AD, Min JC, Shing JL. Asymmetrical Dimethylarginine:A Novel Risk Factor for Coronary Artery Disease. Clin Cardiol.2003;26:458-464..
1. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B.2007; 851:42-50.
2. Tsikas D. A critical review and discussion of analytical methods in the Larginine/ nitric oxide (NO) area of basic and clinical research. Anal Biochem.2008;379 (2): 139-163.
3. Blackwell S, O'Reilly D St J, Talwar D. HPLC analysis of asymmetric dimethylarginine (ADMA) and related arginine metabolites in human plasma using a novel non-endogenous internal standard. Clin Chim Acta.2009;401:14-9.
4. Pettersson A, Uggla L, Backman V. Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. J Chrom B. 1997;692:257-62.
5. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chromatogr B.2007; 851:21-29.
6. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med.2004; 42:1377-1383.
7. Siroka R, Trefil L, Rajdl D, Racek J, Cibulka R. Asymmetric dimethylarginine-comparison of HPLC and ELISA methods. J Chrom B.2007;850:586-7.
8. Dimitrios Tsikas. Determination of asymmetric dimethylarginine in biological fluids: a paradigm for a successful analytical story. Curr Opin Clin Nutr Metab Care. 2008; 11:592-600.
9. Schwedhelm E, Tan-Andreesen J,Maas R, et al. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem.2005; 51:1268-1271.
10. Kirchherr H, Ku hn-Velten WN. HPLC-tandem mass spectrometric method for rapid quantification of dimethylarginines in human plasma. Clin Chem.2005;51:249-252.
11. Schwedhelm E, Xanthakis V, Maas R, et al. Asymmetric Dimethylarginine Reference Intervals Determined with Liquid Chromatography-Tandem Mass Spectrometry: Results from the Framingham Offspring Cohort. Clin Chem.2009;55:1539-1545.
1. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol.2004;44:671-719.
2. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non_ST-Elevation Myocardial Infarction):Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148-e304.
3. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease:2006 Update. J Am Coll Cardiol. 2006;47:2130-2139.
4. Azar RR, Aoun G, Fram DB, Waters DD, Wu AHB, Kiernam FJ. Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am J Cardiol.2000;86:205-207.
5. Tse ML, Yu AD, Min JC, Shing JL. Asymmetrical dimethylarginine:a novel risk factor for coronary artery disease. Clin Cardiol.2003;26:458-464.
6. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events. Arch Intern Med.2003;163:2345-2353.
7. LU TM, YU AD, MIN JC, SHING JL. Asymmetrical Dimethylarginine:A Novel Risk Factor for Coronary Artery Disease. Clin Cardiol.2003;26:458-464.
8. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet.2001;358:2127-8.
9. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease:results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J.2006; 152(493):e1-8.
10. Frobert O, Hjortshoj SP, Simonsen U, Ravkilde J. Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization. Int J Cardiol.2008; 129:288-291.
11.Krempl TK, Maas R, Sydow K, Meinertz T, Boger RH, Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J.2005;26:1846-51.
12. Castillo L, Chapman TE, Sanchez M, et al. Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. Proc Natl Acad Sci USA.1993; 90:7749-7753.
13. Tang WH, Wang ZN, Cho L, Brennan DM, Hazen SL. Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular Risk. J Am Coll Cardiol.2009;53:2061-2067.
14. Erdely A, Kepka-Lenhart D, Salmen Rebecca, et al. Systemic changes in arginase and arginine metabolism in a model of atherosclerosis:a comparison of apoE-/- and C57 mice. The FASEB Journal.2007;21:967.
15. Romero MJ, Platt DH, Tawfik HE, et al. Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity. Circ Res.2008;102:95.
16. Kashyap SR, Lara A, Zhang RL, et al. Insulin Reduces Plasma Arginase Activity in Type 2 Diabetic Patients. Diabetes Care.2008; 31 (1):134-139.
17. Demougeota C, Prigent-Tessierb A, Bagnost T, et al. Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci.2007;80(12): 1128-1134.
18. Bagnost T, Berthelot A, Bouhaddi M, et al. Treatment with the arginase inhibitor N[omega]-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure n adult spontaneously hypertensive rat. J Hypertens.2008:26(6): 1110-1118.
19. Holowartz LA, Kenney WL. Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans. J Physiol.2007; 581:863-872.
20. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B.2007; 851:42-50.
21. Tsikas D. A critical review and discussion of analytical methods in the Larginine/ nitric oxide (NO) area of basic and clinical research. Anal Biochem.2008; 379(2):139-163.
22. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocys(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000; 20:1557-64.
23. L Vladimirova-Kitova, T Deneva, E Angelova, F Nikolov, B Marinov and N Mateva. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging.2008; 28:417-425.
24. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction:its role in hypercholesterolemia. Circulation.1998; 98:1842-7.
25. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DEL. Relations between asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis.2006; 184:383-8.
26. Maas R, Quitzau K, Schwedhelm E, et al. Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. Atherosclerosis.2007; 191:211-9.
27. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease. Results from the Athero Gene study. Circ Res.2005; 97:e53-9.
28. Zeller M, Korandji C, Guilland JC, et al. Impact of asymmetric dimethytlarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol.2008; 28:954-60.
29. Tang WH, Wilson T, Kevin S, et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J.2008; 29:2506-2513.
30. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet.1992; 339:572-5.
31. Jacobi J, Tsao P. Asymmetrical dimethylarginine in renal disease:limits of variation or variation limits? A systematic review. Am JNephrol.2008; 28:224-37.
32. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet.1992; 339:572-575.
33. Palm F, Onozato MI, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH):expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol.2007; 239:H3227-3245.
34. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S. Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci.1998; 62:2425-2430.
35. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, Okumura K. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure:role in reduction of plasma nitric oxide level. Heart Vessels.2003; 18:177-182.
36. Lieba W, Benndorfb RA, Benjamina EJ, et al. Plasma asymmetric dimethylarginine, 1-arginine and left ventricular structure and function in a community-based sample. Atherosclerosis.2009; 204:282-287.
37. Sahinarslan A, Cengel A, Biberoglu G, Hasanoglu A, Turkoglu S, Timurkaynak T. Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. Coron Artery Dis.2006; 17:605-9.
38. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen risk and cardiovascular health study). Clin Chem.2007; 53:273-83.
39. Wang ZN, Tang WH, Cho L, Brennan DM, Hazen SL. Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular Risks:Potential Mechanisms Beyond Nitric Oxide Synthase Inhibition. Arterioscler Thromb Vase Biol.2009; 29:1383-1391.
40. Cavusoglu E, Ruwendec C, Chopra V, et al. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. ACS. Coron Artery Dis.2009; 20:112-117.
41.Nicholls SJ, Wang Z, Koeth R, et al. Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction. Circulation.2007; 116:2315-2324.
42. Duckelmann C, Mittermayer F, Haider DG, et al. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol.2007; 27:2037-42.
43. Duckelmann C, Mittermayer F, Haider DG, et al. Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure. Translational Research.2008; 152:24-30.
44. Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol.2006; 26:2536-40.
45. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P. Plasma concentration of asymmetric dimethylarginine predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care.2008; 31:747-52.
46. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care.2007; 30:1834-9.
47. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HO. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J.2003; 24:1912-9.
48. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking and risk of coronary heart disease in apparently healthy men:prospective analysis from the population-based monitoring of trends and determinants in cardiovascular disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and experimental data. Clin Chem.2007; 53:693-701.
49. Boger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009; 119:1592-600.
50. Leong T, Zylberstein D, Graham I, et al. Asymmetric dimethylarginine independently predicts fatal and non-fatal myocardial infarction and stroke in women.24 year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol.2008;28:961-7.
51.Bae SW, Stuhlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol, 2005;95:729-33.
52. Rosenson RS. Biomarkers, Atherosclerosis and Cardiovascular Events. Expert Rev Cardiol Ther.2008;6(5):619-622.
1. Ferid Murad. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med.2006; 355:2003-2011.
2. John P Cooke. Does ADMA Cause Endothelial Dysfunction? Arterioscler Thromb Vasc Biol.2000; 20:2032-2037.
3. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation.2000;101:948-954.
4. Bedford, M. T. and Richard, S. Arginine methylation an emerging regulator of protein function. Mol Cell.2005; 18,263-272.
5. Kakimoto Y, Akazawa S. Isolation and identification of NG,NG and NG,N'G dimethyl-arginine, Ne-mono, di, and trimethyllysine, and glucosylgalactosyl-and galactosyldl-d-hydroxylysine from human urine. J Biol Chem.1970;230:5751-5758.
6. Paik WK, Kim S. Protein methylase I. Purification and properties of the enzyme. J Biol Chem.1968;243:2108-14.
7. Ghosh SK, Paik WK, Kim S. Purification and molecular identification of two protein methylases I from calf brain. Myelin basic protein- and histone-specific enzyme. J Biol Chem.1988;263:19024-33.
8. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med.2005;10:S3-9.
9. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells:involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res.2000;87:99-105.
10. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumuru K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension.2003;42:985-90.
11. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-9.
12. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-5.
13. Palm F, Onozato MI, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH):expression, regulation, and function in the cardiovascular and renal systems. Am JPhysiol Heart Circ Physiol. 2007;239:H3227-45.
14. McDermott JR. Studies on the catabolism of NG-methylarginine, NG,N'G-dimethyl-arginine and NG,NG-dimethylarginine in the rabbit. Biochem J. 1976;154:179-84.
15. Ogawa T, Kimoto M, Sasoka K. Purification and properties of a new enzyme. NG,NG dimethylarginine dimethylaminohydrolase from rat kidney. J Biol Chem. 1989;264:10205-9.
16. Wang D, Pritmohinder SG, Chabrashvili T, et al. Isoform-specific regulation by NG,NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res. 2007;101:627-35.
17. Nijveldt RJ, van Leeuwen PAM, van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant.2002; 17:1999-2002.
18. Richir MC, Bouwman RH, Teerlink T, et al. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. J Parent Ent Nutr.2008;32:613-22.
19. Murray-Rust J, Leiper JM, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylamino-hydrolases. Nat Struct Biol.2001;8:679-83.
20. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99:3092-5.
21. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus. Role of asymmetric dimethylarginine and dimethylarginine dimethylamino-hydrolase. Circulation.2002; 106:987-92.
22. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation.2001;104:2569-75.
23. Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. Adverse effects of cigarette smoke on NO availability. Role of arginine metabolism and oxidative stress. Hypertension.2006;48:278-85.
24. Sydow K, Munzel T. ADMA and oxidative stress. Atherosclerosis Suppl. 2003;4:41-51.
25. Kielsten JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172-7.
26. Kielstein JT, Simmel S, Bode-Boger SM, et al. Sub-pressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res.2004;27:143-7.
27. Schwedhelm E. Quantification of ADMA:analytical approaches. Vasc Med. 2005;10:S89-95
28. Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. JBiol Chem.2007;282:879-87.
29. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide.1997;1:65-73.
30. Bode-Boger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine:a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol.2006;17:1128-34.
31. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocys(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol.2000;20:1557-64.
32. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction:its role in hypercholesterolemia. Circulation.1998;98:1842-7.
33. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DEL. Relations between asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis.2006; 184:383-8.
34. Maas R, Quitzau K, Schwedhelm E, et al. Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. Atherosclerosis.2007; 191:211-9.
35. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease. Results from the AtheroGene study. Circ Res.2005;97:e53-9.
36. Maas R, Schwedhelm E, Kahl L, et al. Simultaneous assessment of endothelial function, nitric oxide synthase activity. Niric oxide-mediated signalling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem. 2008;54:292-300.
37. L Vladimirova-Kitova, T Deneva, E Angelova, F Nikolov, B Marinov and N Mateva. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging.2008; 28:417-425.
38. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol.2004;94:157-61.
39. Oguz A, Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J. 2008;49:303-11.
40. Young JM, Strey CH, George PM. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. Eur J Heart Failure.2008; 10:463-6.
41.Panichi V, Mantuano E, Paoletti S. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol. 2008;21:38-44.
42. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis.2003; 166:279-84.
43. Janatuinen T, Laakso J, Laaksonen R, et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vase Med.2003;8:185-9.
44. Boger GI, Rudolph TK, Maas R, et al. Asymmetric dimethylarginine determines the improvement of endothelial-dependent vasodilation by simvastatin. Effect of combination with L-arginine. JAm Coll Cardiol. 2007;49:2274-82.
45. Laufs U, La Fata V, Plutzky J, Liao JK. Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation.1998;97:1129-35.
46. Ivashchenko CY, Bradley BT, Ao Z, et al. Regulation of the ADMA-DDAH system in endothelial cells:a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. Am J Physiol Heart Circ Physiol.2010; 298:H251-H258.
47. Sydow K, Mondon CE, Cooke JP. Insulin resistance:potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med.2005;10:S35-43.
48. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA.2002; 106:987-92.
49. Okyay K, Cengel A, Sahinarslan A, et al. Plasma asymmetric dimethylarginine and L-arginine levels in patients with cardiac syndrome X. Coronary Artery Dis. 2007;18:539-44.
50. Anderson JL, Carlquist JF, Roberts WL, et al. Asymmetric dimethylarginine, cortisol/cortisone ratio and C-peptide:markers for diabetes and cardiovascular risk? Am Heart J.2007; 153:67-73.
51.Mittermayer F, Kautzky-Willer A, Winzer C, et al. Elevated concentrations of asymmetric dimethylarginine are associated withdeterioration of glucose tolerance in women with previous gestational diabetes mellitus. J Intern Med.2007;261:392-8.
52. McLaughlin T, Stuhlinger M, Lamendola C, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab.2006;91:1896-900.
53. Krzyzanowska K, Mittermayer F, Shnawa N, et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med.2007;24:81-6.
54. Asagami T, Abbasi F, Stulinger C, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002;51:843-6.
55. Kelly AS, Thelen AM, Kaiser DR., Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vase Med.2007; 12:311-8.
56. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. all-trans-retinoic acid increases nitric oxide synthesis by asymmetric dimethylarginine:role of dimethylarginine dimethylaminohydrolase. CircRes.2003;92:226-33.
57. Yasuda S, Miyazaki S, Kanda M, et al. Intensive treatment of risk factors in patients with type 2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase. Eur Heart J.2006;27:1159-65.
58. Jacobi J, Tsao P. Asymmetrical dimethylarginine in renal disease:limits of variation or variation limits? A systematic review. Am JNephrol.2008;28:224-37.
59. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease:a competing risks modelling approach. J Am Soc Nephrol. 2005;16:2449-55.
60. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease:the mild to moderate kidney disease study. J Am Soc Nephrol.2005; 16:2456-61.
61. Zoccali C, Bendetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol.2002; 13:490-6.
62. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodelling and asymmetric dimethylarginine in haemodialysis patients. Kidney Int. 2002;62:339-45.
63. Zoccali C, Bode-Boger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
64. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol.1999;33:652-8.
65. Delles C, Schnieder MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin Ⅱ AT1-receptor blockade reduce the levels of asymmetrical N(G),N(G)-dimethylarginine in human essential hypertension. Am J Hypertens.2002; 15:590-3.
66. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibtion induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004;148:e5.
67. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide availability and coronary microvascular function in patients with syndrome X. Am J Cardiol.2002;90:974-82.
68. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitorin patients with type 2 diabetes mellitus. Circ J. 2002;66:811-5.
69. Yilmaz MI, Saglam M, Sonmez A, et al. Improving proteinuria, endothelial fiunctions and asymmetric dimethylarginine levels in chronic kidney disease:ramipril versus valsartan. Blood Purif.2007;25:324-6.
70. Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine Impairs the Nitric Oxide Synthase Pathway:Role of Asymmetric Dimethylarginine. Circulation. 2001;104;2569-2575.
71. Markus CS, Roberta KO, Eric EG, Isabella S, et al. Endothelial Dysfunction Induced by Hyperhomocyst(e)inemia:Role of Asymmetric Dimethylarginine. Circulation. 2003;108:933-938.
72. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S. Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci.1998;62:2425-2430.
73. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, Okumura K. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure:role in reduction of plasma nitric oxide level. Heart Vessels.2003;18:177-182.
74. WH Wilson Tang, Wilson T, Kevin S, et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J.2008; 29:2506-2513.
75. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation.1999;99:1141-1146.
76. Furuki K, Adachi H, Matsuoka H, et al. Plasma levels of asymmetric dim ethyl arginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis.2007;191:206-210.
77. Wanby P, Nilsson I, Brudin L, et al. Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis:no evidence for the role of the common FABP2 A54T gene polymorphism. Acta Neurol Scand.2007; 115:90-96.
78. Chirinos JA, David R, Bralley JA, et al. Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease:the PREVENCION Study. Hypertension.2008;52:1051-1059.
79. Furuki K, Adachi H, Enomoto M, et al. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression:six-year prospective study using carotid ultrasonography. Hypertens Res.2008;31:1185-1189.
80. Renke M, Vanessa X, Joseph FP, et al. Association of the Endogenous Nitric Oxide Synthase Inhibitor ADMA With Carotid Artery Intimal Media Thickness in the Framingham Heart Study Offspring Cohort. Stroke.2009;40:2715-2719.
81. Iribarren C, Husson G, Sydow K, et al. Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age:the CARDIA Study. Eur J Cardiovasc Prev Rehabil.2007; 14:222-229.
82. Selcuk MT, Selcuk H, Temizhan A, et al. Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow. Coron Artery Dis.2007; 18:545-551.
83. Kocaman SA, Sahinarslan A, Biberoglu G, et al. Asymmetric dimethylarginine and coronary collateral vessel development. Coron Artery Dis.2008; 19:469-474.
84. Sun T, Huang Y, Phillips MI, et al. Growth Differentiation Factor 15 and Coronary Collateral Formation. Clin Cardiol. (in press).
85. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease:results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J.2006;152:493:el-8.
86. Elesber AA, Solomon H, Lennon RJ, et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J.2006;27:824-31.
87. Sahinarslan A, Cengel A, Biberoglu G, Hasanoglu A, Turkoglu S, Timurkaynak T. Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. Coron Artery Dis.2006; 17:605-9.
88. Lu TM, Yu AD, Min JC, Shing JL. Asymmetrical Dimethylarginine:A Novel Risk Factor for Coronary Artery Disease. Clin Cardiol.2003;26:458-464.
89. Joyal D, Leya F, Al-Chekakie MO, et al. Presence of asymmetric dimethylarginine gradients across high-grade lesions in patients with coronary artery disease. Coron Art Dis.2001;18:471-5.
90. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet.2001;358:2127-8.
91.Meinitzer A, Seelhorst U,Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen risk and cardiovascular health study). Clin Chem.2007;53:273-83.
92. Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL. Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular Risks:Potential Mechanisms Beyond Nitric Oxide Synthase Inhibition. Arterioscler Thromb Vasc Biol. 2009;29:1383-1391.
93. Zeller M, Korandji C, Guilland JC, et al. Impact of asymmetric dimethytlarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2008;28:954-60.
94. Cavusoglu E, Ruwendec C, Chopra V, et al. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. ACS. Coron Artery Dis.2009;20:112-117.
95. Nicholls SJ, Wang Z, Koeth R, et al. Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction. Circulation. 2007; 116:2315-2324.
96. Duckelmann C, Mittermayer F, Haider DG, et al. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol.2007;27:2037-42.
97. Duckelmann C, Mittermayer F, Haider DG, et al. Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure. Translational Research.2008;152:24-30.
98. Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol.2006;26:2536-40.
99. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P. Plasma concentration of asymmetric dimethylarginine predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2008;31:747-52.
100. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care.2007;30:1834-9.
101. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HO. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J.2003;24:1912-9.
102. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking and risk of coronary heart disease in apparently healthy men:prospective analysis from the population-based monitoring of trends and determinants in cardiovascular disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and experimental data. Clin Chem.2007;53:693-701.
103. Boger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation.2009; 119:1592-600.
104. Leong T, Zylberstein D, Graham I, et al. Asymmetric dimethylarginine independently predicts fatal and non-fatal myocardial infarction and stroke in women. 24 year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol.2008;28:961-7.
105. Bae SW, Stuhlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol, 2005;95:729-33.
106. Krempl TK, Maas R, Sydow K, Meinertz T, Boger RH, Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J.2005;26:1846-51.
107. Blackwell S, O'Reilly D St J, Talwar D. HPLC analysis of asymmetric dimethylarginine (ADMA) and related arginine metabolites in human plasma using a novel non-endogenous internal standard. Clin Chim Acta.2009;401:14-9.
108. Meinitzer A, Puchinger M, Winkelhofer-Roob BM, et al. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta. 2007;384:141-8.
109. Pettersson A, Uggla L, Backman V. Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. J Chrom B. 1997;692:257-62.
110. Bishop MJ, Crow B, Norton D, Paliakov E, George J, Bralley JA. Direct analysis of underivatized asymmetric dimethylarginine (ADMA) and L-arginine from plasma using mixed-mode ion-exchange liquid chromatography-tandem mass spectrometry. J Chrom B.2007;859:164-9.
111. Martens-Lobenhoffer J, Bode-Boger SM. Fast and efficient determination of arginine, symmetric dimethylarginine and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem.2006;52:488-93.
112. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004;42:1377-83
113. Siroka R, Trefil L, Rajdl D, Racek J, Cibulka R. Asymmetric dimethylarginine-comparison of HPLC and ELISA methods. J Chrom B.2007;850:586-7.
114. Bode-Boger SM, Boger RH, Creutzig A, et al. L-Arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy volunteers. Clin Sci.1994; 87:303-310.
115. Bode-Boger SM, Boger RH, Alfke H, et al. L-Arginine induces NO-dependent vasodilation in patients with critical limb ischemia - a randomized, controlled study. Circulation.1996; 93:85-90.
116. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol.1997; 80:331-333.
117. Bednarz B, Wolk R, Chamiec T, et al. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. Int J Cardiol.2000; 75:205-210.
118. Bednarz B, Jaxa-Chamiec T, Maciejewski P, et al. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol.2005; 62:421-427.
119. Schulman SP, Becker LC, Kass DA, et al. L-Arginine therapy in acute myocardial infarction:the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA.2006; 295:58-64.
120. Wilson AM, Harada R, Nair N, et al. L-Arginine supplementation in peripheral arterial disease:no benefit and possible harm. Circulation.2007; 116:188-195.
121. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chrom B.2007;851:21-9.
122. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH. Determination of a reference value for NG,NG-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest.2005;35:622-6.
123. Blackwell S, O'Reilly D St J, Talwar D. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma. Eur J Clin Invest.2007;37:364-71.